• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Assessing information in T2-weighted MRI scans from secondary progressive MS patients.

作者信息

Koziol J A, Wagner S, Adams H P

机构信息

Department of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, CA 92037, USA.

出版信息

Neurology. 1998 Jul;51(1):228-33. doi: 10.1212/wnl.51.1.228.

DOI:10.1212/wnl.51.1.228
PMID:9674807
Abstract

BACKGROUND

Magnetic resonance imaging is used routinely for diagnosing MS and for objective assessment of the extent of disease as a marker of treatment efficacy in MS clinical trials. Nevertheless, in many clinical studies only weak correlations have been reported between MRI findings and clinical outcome measures.

PURPOSE

The purpose of this study is to compare clinical outcome measures (neurologic scales) with MRI findings (evaluation of T2-weighted MRI scans using a semiautomated quantitative technique and with an independent assessment by a neurologist) in the context of a randomized clinical trial evaluating the efficacy of cladribine for treatment in secondary progressive MS.

METHODS

Baseline, 6-month, and 12-month scans from 41 secondary progressive MS patients were examined and ranked in terms of lesion burden from the quantitative assessment and independently in terms of severity by neurologic evaluation. Comparison is made to monthly Expanded Disability Status Scale (EDSS) and Scripps Neurologic Rating Scale (SNRS) determinations in these patients with a nonparametric statistical procedure.

RESULTS

Average rank correlations between any of the MRI assessment procedures and either clinical outcome measure were less than 0.15 in absolute magnitude. The average rank correlation between the two MRI assessment procedures was 0.10. There is only a weak degree of association between the MRI assessment procedures and the clinical parameters, although the study has statistical power in excess of 0.90 to find even a moderate level of association between them.

CONCLUSIONS

Disease-related activity in T2-weighted scans of secondary progressive MS patients is a multidimensional construct, and is not summarized adequately solely by quantification of overall lesion burden or by assessment of severity. Neither method of summarizing information from T2-weighted scans is strongly related to measures of the clinical course of disease as assessed by the EDSS or SNRS.

摘要

相似文献

1
Assessing information in T2-weighted MRI scans from secondary progressive MS patients.
Neurology. 1998 Jul;51(1):228-33. doi: 10.1212/wnl.51.1.228.
2
Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group.克拉屈滨与进展型多发性硬化症:一项多中心对照试验的临床及磁共振成像结果。克拉屈滨磁共振成像研究组
Neurology. 2000 Mar 14;54(5):1145-55. doi: 10.1212/wnl.54.5.1145.
3
Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite.多发性硬化症临床试验的结果指标:扩展残疾状态量表和多发性硬化症功能综合评分的相对测量精度
Mult Scler. 2004 Feb;10(1):41-6. doi: 10.1191/1352458504ms983oa.
4
MRI as an outcome in multiple sclerosis clinical trials.磁共振成像作为多发性硬化症临床试验的一项结果指标。
Neurology. 2009 Feb 24;72(8):705-11. doi: 10.1212/01.wnl.0000336916.38629.43. Epub 2008 Dec 10.
5
The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.大麻素用于进行性炎症性脑病(CUPID)试验:一项随机双盲安慰剂对照平行组多中心试验及大麻素延缓多发性硬化症进展的经济学评估。
Health Technol Assess. 2015 Feb;19(12):vii-viii, xxv-xxxi, 1-187. doi: 10.3310/hta19120.
6
Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.多发性硬化症中每月增强MRI病灶率与T2病灶体积变化之间的相关性。
Ann Neurol. 1998 Mar;43(3):332-9. doi: 10.1002/ana.410430311.
7
Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.继发进展型多发性硬化症患者磁共振成像上的低信号和高信号病变
Eur Neurol. 1999 Jul;42(1):52-63. doi: 10.1159/000008069.
8
Concurrent validity of the MS Functional Composite using MRI as a biological disease marker.使用MRI作为生物学疾病标志物时MS功能综合评分的同时效度。
Neurology. 2001 Jan 23;56(2):215-9. doi: 10.1212/wnl.56.2.215.
9
Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis.神经心理学和磁共振成像测量可预测良性多发性硬化症的短期病情发展。
Neurology. 2009 Aug 18;73(7):498-503. doi: 10.1212/WNL.0b013e3181b351fd. Epub 2009 Jul 29.
10
Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study.
Neurology. 1995 Feb;45(2):255-60. doi: 10.1212/wnl.45.2.255.

引用本文的文献

1
Predictive value of lesions for relapses in relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症中病灶对复发的预测价值。
AJNR Am J Neuroradiol. 2001 Feb;22(2):284-91.